JP2016523906A5 - - Google Patents

Download PDF

Info

Publication number
JP2016523906A5
JP2016523906A5 JP2016523850A JP2016523850A JP2016523906A5 JP 2016523906 A5 JP2016523906 A5 JP 2016523906A5 JP 2016523850 A JP2016523850 A JP 2016523850A JP 2016523850 A JP2016523850 A JP 2016523850A JP 2016523906 A5 JP2016523906 A5 JP 2016523906A5
Authority
JP
Japan
Prior art keywords
optionally substituted
alkyl
hydrogen
group
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016523850A
Other languages
English (en)
Japanese (ja)
Other versions
JP6453322B2 (ja
JP2016523906A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/043841 external-priority patent/WO2014209983A1/en
Publication of JP2016523906A publication Critical patent/JP2016523906A/ja
Publication of JP2016523906A5 publication Critical patent/JP2016523906A5/ja
Application granted granted Critical
Publication of JP6453322B2 publication Critical patent/JP6453322B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016523850A 2013-06-26 2014-06-24 置換ヌクレオシド、置換ヌクレオチドおよびそれらの類似体 Expired - Fee Related JP6453322B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361839756P 2013-06-26 2013-06-26
US61/839,756 2013-06-26
PCT/US2014/043841 WO2014209983A1 (en) 2013-06-26 2014-06-24 Substituted nucleosides, nucleotides and analogs thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018232331A Division JP2019059766A (ja) 2013-06-26 2018-12-12 置換ヌクレオシド、置換ヌクレオチドおよびそれらの類似体

Publications (3)

Publication Number Publication Date
JP2016523906A JP2016523906A (ja) 2016-08-12
JP2016523906A5 true JP2016523906A5 (enExample) 2017-08-03
JP6453322B2 JP6453322B2 (ja) 2019-01-16

Family

ID=52116188

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016523850A Expired - Fee Related JP6453322B2 (ja) 2013-06-26 2014-06-24 置換ヌクレオシド、置換ヌクレオチドおよびそれらの類似体
JP2018232331A Withdrawn JP2019059766A (ja) 2013-06-26 2018-12-12 置換ヌクレオシド、置換ヌクレオチドおよびそれらの類似体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018232331A Withdrawn JP2019059766A (ja) 2013-06-26 2018-12-12 置換ヌクレオシド、置換ヌクレオチドおよびそれらの類似体

Country Status (22)

Country Link
US (3) US9422322B2 (enExample)
EP (2) EP3424938B1 (enExample)
JP (2) JP6453322B2 (enExample)
KR (1) KR20160023711A (enExample)
CN (1) CN105408341B (enExample)
AP (1) AP2015008954A0 (enExample)
AU (2) AU2014302715B2 (enExample)
BR (1) BR112015031763A2 (enExample)
CA (1) CA2913210C (enExample)
CL (1) CL2015003615A1 (enExample)
DK (2) DK3424938T3 (enExample)
EA (1) EA201592075A1 (enExample)
ES (2) ES2825035T3 (enExample)
GE (1) GEP201706793B (enExample)
MX (1) MX2015017556A (enExample)
NZ (1) NZ714415A (enExample)
PE (1) PE20160205A1 (enExample)
PH (1) PH12015502799A1 (enExample)
SG (1) SG11201509585YA (enExample)
TW (1) TWI655199B (enExample)
UA (1) UA118760C2 (enExample)
WO (1) WO2014209983A1 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2619215B1 (en) 2010-09-22 2018-09-05 Alios Biopharma, Inc. Azido nucleosides and nucleotide analogs
EP2655392B1 (en) 2010-12-22 2018-04-18 Alios Biopharma, Inc. Cyclic nucleotide analogs
US8980865B2 (en) 2011-12-22 2015-03-17 Alios Biopharma, Inc. Substituted nucleotide analogs
SG10201610936RA (en) 2011-12-22 2017-02-27 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US8916538B2 (en) 2012-03-21 2014-12-23 Vertex Pharmaceuticals Incorporated Solid forms of a thiophosphoramidate nucleotide prodrug
HUE029038T2 (en) 2012-05-25 2017-01-30 Janssen Sciences Ireland Uc Uracil spirooxetan nucleosides
US9598457B2 (en) 2012-12-21 2017-03-21 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
GEP201706757B (en) 2012-12-21 2017-10-25 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
AU2014248116A1 (en) 2013-04-05 2015-11-12 Alios Biopharma, Inc. Hepatitis C viral infection treatment using a combination of compounds
EP3424938B1 (en) 2013-06-26 2020-07-22 Janssen BioPharma, Inc. 4'-azidoalkyl-substituted nucleosides, nucleotides and analogs thereof
HK1224229A1 (zh) * 2013-06-26 2017-08-18 Alios Biopharma, Inc. 取代的核苷,核苷酸及其类似物
JP6562908B2 (ja) 2013-10-11 2019-08-21 ヤンセン バイオファーマ インク. 置換ヌクレオシド、置換ヌクレオチドおよびその類似体
HUE051986T2 (hu) 2014-06-24 2021-04-28 Janssen Biopharma Inc Helyettesített nukleozidok, nukleotidek és analógjaik virális fertõzés kezelésére való alkalmazásra
TN2016000566A1 (en) 2014-06-24 2018-04-04 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
JP2017523988A (ja) * 2014-08-05 2017-08-24 アリオス バイオファーマ インク. パラミクソウイルスを治療するための併用療法
HK1243714A1 (zh) 2014-10-28 2018-07-20 Alios Biopharma, Inc. 制备取代的核苷类似物的方法
CN105254695B (zh) * 2014-11-10 2019-01-18 南京曼杰生物科技有限公司 核苷氨基磷酸酯衍生物及其应用
MA41441A (fr) 2014-12-19 2017-12-12 Alios Biopharma Inc Nucléosides substitués, nucléotides et analogues de ceux-ci
MA41213A (fr) 2014-12-19 2017-10-24 Alios Biopharma Inc Nucléosides substitués, nucléotides et analogues de ceux-ci
EA036776B1 (ru) 2015-03-11 2020-12-21 Янссен Байофарма, Инк. Соединения азапиридона и способы их применения
US10011629B2 (en) * 2015-05-01 2018-07-03 Cocrystal Pharma, Inc. Nucleoside analogs for treatment of the flaviviridae family of viruses and cancer
MY197231A (en) 2015-07-22 2023-06-06 Enanta Pharm Inc Benzodiazepine derivatives as rsv inhibitors
US10202412B2 (en) 2016-07-08 2019-02-12 Atea Pharmaceuticals, Inc. β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections
WO2019067864A1 (en) * 2017-09-29 2019-04-04 Enanta Pharmaceuticals, Inc. PHARMACEUTICAL AGENTS IN COMBINATION AS INHIBITORS OF RSV
WO2020057546A1 (zh) 2018-09-21 2020-03-26 上海迪诺医药科技有限公司 环状二核苷酸类似物、其药物组合物及应用
CA3133300A1 (en) 2019-03-18 2020-09-24 Enanta Pharmaceuticals, Inc. Benzodiazepine derivatives as rsv inhibitors
US11505558B1 (en) 2019-10-04 2022-11-22 Enanta Pharmaceuticals, Inc. Antiviral heterocyclic compounds
WO2021216722A1 (en) * 2020-04-23 2021-10-28 Atea Pharmaceuticals, Inc. Stereoselective process of manufacture of purine phosphoramidates
WO2022086840A1 (en) 2020-10-19 2022-04-28 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as anti-viral agents
US12274700B1 (en) 2020-10-30 2025-04-15 Accencio LLC Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors
US12612412B2 (en) 2021-02-26 2026-04-28 Enanta Pharmaceuticals, Inc. Antiviral heterocyclic compounds
CN114773417B (zh) * 2022-04-06 2023-08-22 郑州大学 一种虫草素磷酸酯及其制备方法与应用
AR129003A1 (es) 2022-04-07 2024-07-03 Enanta Pharm Inc Compuestos heterocíclicos antivirales
WO2023211997A1 (en) 2022-04-27 2023-11-02 Enanta Pharmaceuticals, Inc. Antiviral compounds

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5674998A (en) 1989-09-15 1997-10-07 Gensia Inc. C-4' modified adenosine kinase inhibitors
US5432272A (en) 1990-10-09 1995-07-11 Benner; Steven A. Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
SI1355916T1 (sl) 2001-01-22 2007-04-30 Merck & Co Inc Nukleozidni derivati kot inhibitorji RNA-odvisne RNA virusne polimeraze
GB0114286D0 (en) * 2001-06-12 2001-08-01 Hoffmann La Roche Nucleoside Derivatives
US7951789B2 (en) 2006-12-28 2011-05-31 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
EP2229459B1 (en) 2007-12-13 2014-08-27 Alnylam Pharmaceuticals, Inc. Methods and compositions for prevention or treatment of RSV infection
CL2009002206A1 (es) 2008-12-23 2011-08-26 Gilead Pharmasset Llc Compuestos derivados de pirrolo -(2-3-d]-pirimidin-7(6h)-tetrahidrofuran-2-il fosfonamidato, composicion farmaceutica; y su uso en el tratamiento de enfermedades virales.
AU2010226466A1 (en) 2009-03-20 2011-10-20 Alios Biopharma, Inc. Substituted nucleoside and nucleotide analogs
WO2012040126A1 (en) 2010-09-22 2012-03-29 Alios Biopharma, Inc. Substituted nucleotide analogs
EP2619215B1 (en) 2010-09-22 2018-09-05 Alios Biopharma, Inc. Azido nucleosides and nucleotide analogs
GEP20156313B (en) 2010-09-22 2015-07-10 Alios Biopharma Inc Substituted nucleotide analogs
EP2655392B1 (en) 2010-12-22 2018-04-18 Alios Biopharma, Inc. Cyclic nucleotide analogs
US8980865B2 (en) 2011-12-22 2015-03-17 Alios Biopharma, Inc. Substituted nucleotide analogs
SG10201610936RA (en) 2011-12-22 2017-02-27 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
US8916538B2 (en) 2012-03-21 2014-12-23 Vertex Pharmaceuticals Incorporated Solid forms of a thiophosphoramidate nucleotide prodrug
HK1203513A1 (en) 2012-03-21 2015-10-30 艾丽奥斯生物制药有限公司 Methods of preparing substituted nucleotide analogs
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
RS58437B1 (sr) 2012-03-21 2019-04-30 Alios Biopharma Inc Supstituisani nukleozidi, nukleotidi i njihovi analozi
WO2013142159A1 (en) 2012-03-21 2013-09-26 Alios Biopharma, Inc. Pharmaceutical combinations comprising a thionucleotide analog
EP2827876A4 (en) 2012-03-22 2015-10-28 Alios Biopharma Inc PHARMACEUTICAL COMBINATIONS WITH A THIONUCLEOTIDE ANALOG
GEP201706757B (en) 2012-12-21 2017-10-25 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
US9598457B2 (en) 2012-12-21 2017-03-21 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
TW201526899A (zh) 2013-02-28 2015-07-16 Alios Biopharma Inc 醫藥組成物
WO2014164533A1 (en) 2013-03-11 2014-10-09 Vertex Pharmaceuticals Incorporated Methods of stereoselective synthesis of substituted nucleoside analogs
AU2014248116A1 (en) 2013-04-05 2015-11-12 Alios Biopharma, Inc. Hepatitis C viral infection treatment using a combination of compounds
EP3424938B1 (en) 2013-06-26 2020-07-22 Janssen BioPharma, Inc. 4'-azidoalkyl-substituted nucleosides, nucleotides and analogs thereof
HK1224229A1 (zh) 2013-06-26 2017-08-18 Alios Biopharma, Inc. 取代的核苷,核苷酸及其类似物
JP6562908B2 (ja) 2013-10-11 2019-08-21 ヤンセン バイオファーマ インク. 置換ヌクレオシド、置換ヌクレオチドおよびその類似体
TN2016000566A1 (en) 2014-06-24 2018-04-04 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
BR112016029994A2 (pt) 2014-06-24 2017-08-22 Alios Biopharma Inc métodos de preparação de análogos de nucleotídeo substituídos
HUE051986T2 (hu) 2014-06-24 2021-04-28 Janssen Biopharma Inc Helyettesített nukleozidok, nukleotidek és analógjaik virális fertõzés kezelésére való alkalmazásra
JP2017525681A (ja) 2014-07-22 2017-09-07 アリオス バイオファーマ インク. パラミクソウイルスの治療方法
JP2017523988A (ja) 2014-08-05 2017-08-24 アリオス バイオファーマ インク. パラミクソウイルスを治療するための併用療法
HK1243714A1 (zh) 2014-10-28 2018-07-20 Alios Biopharma, Inc. 制备取代的核苷类似物的方法
MA41441A (fr) 2014-12-19 2017-12-12 Alios Biopharma Inc Nucléosides substitués, nucléotides et analogues de ceux-ci
MA41213A (fr) 2014-12-19 2017-10-24 Alios Biopharma Inc Nucléosides substitués, nucléotides et analogues de ceux-ci
US20190169221A1 (en) 2016-08-12 2019-06-06 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
WO2018081449A1 (en) 2016-10-27 2018-05-03 Alios Biopharma, Inc. Methods for treating respiratory syncytial virus infection
CA3075950A1 (en) 2017-09-18 2019-03-21 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof

Similar Documents

Publication Publication Date Title
EP3362451B1 (en) Inhibitors of influenza virus replication, application methods and uses thereof
JP2017538722A5 (enExample)
JP2020534361A5 (enExample)
EA201591390A1 (ru) Пиразол[1,5-a]пиримидины для противовирусного лечения
ES2616784T3 (es) Quinoxalinonas y dihidroquinoxalinonas como agentes antivíricos contra el virus sincitial respiratorio
JP2015510946A5 (enExample)
SG179445A1 (en) Nucleoside phosphoramidate prodrugs
AR090699A1 (es) Compuestos inhibidores de la actividad de la arn polimerasa viral
EA201391158A8 (ru) Диаминиевые соли фенотиазина и их применение
PH12014501134A1 (en) 2',4'-difluoro-2'-methyl substituted nucleoside derivatives as inhibitors of hcv rna replication
BR112015023705A2 (pt) composto da fórmula (ia) ou um sal, hidrato, solvato ou forma cristalina farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto, composto e método para síntese do composto da fórmula (ia)
CY1119015T1 (el) 4'-αζιδο-3'φθορο υποκατεστημενα νουκλεοζιδιου παραγωγα ως αναστολεις αντιγραφης hcv rna
BR112015009395A2 (pt) processo para preparação de derivados do ácido biliar
EA201590020A1 (ru) Новые производные 1,3-дигидро-2h-бензимидазол-2-она, замещенные бензимидазолами, в качестве противовирусных средств против респираторного синцитиального вируса
IN2014MN02106A (enExample)
AR093659A1 (es) Derivados ciclicos de nucleosidos y usos de los mismos
BR112013011593A2 (pt) cristal de derivado de morfinan 7-carbamoíla-6,7-insaturada e método para produzir o mesmo
EA201270492A1 (ru) Соединения для лечения дислипидемии и связанных с ней заболеваний
HK1200812A1 (en) Rod -like hepatitis c virus inhibitors containing the fragement {2- [4- (bi phenyl - 4 - yl) - 1h - imidazo - 2 - yl] pyrrolidine - 1 - carbonlymethyl} amine
CN108727369B (zh) 流感病毒复制抑制剂及其用途
MX378555B (es) Proceso para la preparacion de derivados del acido biliar de las sulfonilureas
WO2012174312A3 (en) Benzimidazole derivatives as antiviral agents
WO2016005330A1 (en) Dihydropyridopyrazine-1,8-diones and their use in the treatment, amelioration or prevention of viral diseases
WO2015011120A3 (en) Salts of dasatinib in crystalline form
CN104829627A (zh) 一种手性六氢呋喃并[2,3-b]呋喃-3-甲胺及其制备方法及应用